How Indian contract manufacturers are emerging as strategic innovation partners

Over the past two decades, India’s Contract Development and Manufacturing Organisation (CDMO) sector has undergone a remarkable transformation. What was once viewed primarily as a cost-efficient manufacturing destination has steadily evolved into a globally relevant innovation engine. Today, this evolution is accelerating with the emergence of CDMO 4.0, in which digital technologies are reshaping how pharmaceutical and speciality chemical manufacturing is designed, executed and scaled.

Redefining the future of contract manufacturing

Worldwide, pharmaceutical manufacturing is undergoing a deep transformation driven by digital technologies, automation and data-driven decision-making. As drug development becomes increasingly complex and market demands continue to evolve, CDMOs are expected to deliver manufacturing capacity, agility, transparency, quality and innovation. This evolution has given rise to the concept of CDMO 4.0.

CDMO 4.0 represents the integration of Industry 4.0 and Pharma 4.0 principles into contract development and manufacturing operations. By leveraging technologies such as artificial intelligence (AI), Industrial Internet of Things (IIoT), cloud computing, advanced analytics and digital twins, CDMOs are creating intelligent, connected and highly efficient manufacturing ecosystems.

The global pharma CDMO market was estimated at approximately $166bn in 2025 and is projected to grow to nearly $294bn by 2033, driven by increasing outsourcing, the development of complex therapeutics and demand for specialised manufacturing capabilities.

The domestic CDMO industry equally reflects this momentum. Between 2019 and 2023, India’s CDMO market doubled to an estimated $20bn, registering an impressive CAGR of around 18%. Industry estimates project the market to grow from $29.53bn in 2026 to nearly $58bn by 2031. As India advances towards its India@100 vision of building a $450bn pharmaceutical industry by 2047, digitally enabled CDMOs will play an indispensable role in achieving this ambition.

Simultaneously, geopolitical conflicts, tariff realignments, changing trade agreements and global supply chain disruptions have fundamentally altered how innovator companies evaluate manufacturing partners. Flexibility, resilience and transparency have become as important as manufacturing capacity. Against this backdrop, CDMO 4.0 is no longer simply a technology upgrade. It represents a paradigm shift in partnership models, in which data, digital ecosystems and scientific collaboration redefine value creation.

From capacity providers to strategic co-innovation partners

Traditionally, CDMO relationships were largely transactional. Global pharma companies are increasingly moving beyond transactional outsourcing towards strategic manufacturing partnerships that combine development expertise, digital capabilities, regulatory excellence and supply chain flexibility. Success was earlier measured via operational efficiency rather than collaborative innovation. That paradigm is rapidly becoming outdated.

Today, the narrative is no longer about the conventional vendor-client outsourcing relationship focused solely on reducing costs and increasing capacity. Instead, it is about deeply integrated, technology-driven co-innovation ecosystems that have transformed the role of CDMOs from simply acting as manufacturing partners into becoming strategic innovation partners throughout the product lifecycle.

Digital transformation plays a critical role in this shift. Rather than working merely as an operational efficiency tool, digital technologies now serve as the foundation for transparent, agile and collaborative partnerships. Leading CDMOs are gradually participating across the entire product lifecycle from early process development and technology transfer to commercial manufacturing, regulatory support and lifecycle management. Several structural shifts are driving this evolution.

Earlier-stage sponsors particularly benefit from these partnership-driven engagement models, which improve predictability around material planning, manufacturing capacity and commercialisation timelines. Transparent scientific dialogue, supported by structured communication frameworks, enables faster problem-solving and stronger alignment throughout the development lifecycle. Therefore, competitive advantage no longer lies solely in manufacturing scale. It increasingly depends on integrated intelligence, digital maturity, operational transparency and an organisation’s ability to co-create value with its customers.

Technology – CDMO 4.0’s pivotal pillar

The convergence of multiple digital technologies enables the transformation towards CDMO 4.0. Together, they transform traditional manufacturing facilities into connected, intelligent ecosystems. Historically, pharma manufacturing relied largely on manual and siloed operations. Production data was dispersed across multiple systems, quality investigations were reactive and process optimisation depended heavily on human expertise.

CDMO 4.0 basically changes this operating model by replacing paper-centric workflows with digitally connected manufacturing ecosystems powered by automation, real-time analytics and intelligent decision-making. Some of the defining capabilities include real-time data collection and monitoring, end-to-end digital integration, AI and ML (machine learning) capabilities and digital twins. The last capability requires elaboration.

Digital twins are digital replicas of production processes, enabling simulation, optimisation and troubleshooting before physical production begins. They reduce expansion risks substantially while enabling predictive process development. Unlike conventional manufacturing’s ‘black-box’ approach, where production outcomes become visible only after batch completion, digital twins create a transparent ‘glass-box’ manufacturing model.

By constantly synchronising real-time IoT sensor data with virtual process models, digital twins provide immediate visibility into batch performance, process deviations, quality parameters and yield predictions. Transparency enables clients to monitor manufacturing progress throughout production, rather than only after completion, strengthening trust and accelerating decision-making.

Key challenges in the CDMO 4.0 transition

Despite its transformative potential, the transition towards CDMO 4.0 presents several strategic, technological and organisational challenges. Successfully implementing digital manufacturing requires considerably more than investing in new software or automation technologies. It demands a carefully planned transformation strategy supported by leadership commitment, organisational alignment and sustained investment.

Legacy infrastructure, data integration and interoperability, cyber security and intellectual property protection, people and organisational capability, capital investments and the evolving regulatory landscape together pose distinct challenges. Accordingly, the transition to CDMO 4.0 requires both organisational and technological transformation. Success depends on aligning people, processes, technology and culture within a unified digital strategy.

India’s strategic advantage in the CDMO 4.0 era

India enters this new era from a position of considerable strength. For decades, the country’s manufacturing competitiveness was primarily associated with cost efficiency and large-scale production capabilities. While these advantages remain relevant, they no longer define India’s competitive position.

Instead, the next phase of growth will be shaped by the country’s ability to combine process engineering excellence, scientific expertise, digital manufacturing capabilities and sustainability leadership. India already possesses a sturdy foundation in complex chemistry, pharmaceutical manufacturing and process innovation. Its highly skilled scientific workforce, robust manufacturing ecosystem and growing investments in digital technologies position Indian CDMOs favourably to support increasingly sophisticated product portfolios.

Meanwhile, ongoing geopolitical uncertainties continue to encourage multinational pharma firms to diversify their global supply chains beyond conventional manufacturing hubs. This shift offers India an unprecedented opportunity to strengthen its position as a preferred manufacturing destination while expanding its role as an innovation partner.

Another important differentiator is sustainability. As pharma supply chains increasingly adopt Environmental, Social and Governance (ESG) principles, sustainability has become central to manufacturing competitiveness rather than merely being a compliance requirement. Indian CDMOs are responding by integrating sustainability directly into digitally enabled operations.

Real-time monitoring of energy consumption, waste generation and carbon emissions enables manufacturers to continuously improve environmental performance rather than relying on retrospective audits. Investments in green chemistry, safer bio-based solvents, closed-loop solvent recovery systems, Zero Liquid Discharge (ZLD) facilities, renewable energy and advanced wastewater management are becoming increasingly common across leading manufacturing organisations. These initiatives strengthen regulatory compliance while supporting the environmental expectations of global innovators seeking long-term strategic manufacturing partners.

Jubilant Ingrevia: advancing CDMO 4.0 at scale

The evolution of CDMO 4.0 is already being translated into practice by firms that have successfully combined digital transformation with operational excellence and sustainability. Jubilant Ingrevia is one such example, showing how Indian manufacturers are evolving into strategic innovation partners. Its Bharuch manufacturing facility was recognised by the World Economic Forum (WEF) as a Lighthouse Factory in 2024, becoming the first Indian chemical manufacturing facility to receive this distinction for deploying Fourth Industrial Revolution (4IR) technologies at scale. The recognition reflects its successful integration of digital technologies to enhance manufacturing agility, operational efficiency and process reliability.

By providing end-to-end solutions, the firm supports small-molecule NCEs from Phase I–III through commercial launches, including regulatory starting materials and advanced intermediates. Its USFDA-inspected cGMP unit in Bharuch, integrated development-to-manufacturing platform and regulatory expertise ensure seamless tech transfer and inspection-ready global supply. Three streams in an ISO 8 cleanroom are designed to accommodate multiple products with diverse chemistries and operate in accordance with global regulatory norms.

From concept to commercialisation, integrated expertise spans every stage of development and manufacturing. In the R&D process, the firm is innovating and developing next-generation molecules with scientific excellence, while its process optimisation is enhancing efficiency, yield and sustainability through continuous process improvement. Similarly, scale-up studies are generating robust data and confidently developing scalable processes. The commercial process is exemplified by reliable, efficient and cost-effective manufacturing done at commercial scale. For regulatory filings, there is end-to-end support to ensure compliance.

In pharmaceuticals, Jubilant Ingrevia works with global companies to efficiently and safely bring small-molecule medicines to market. Core intermediates, solvents and CDMO services support the development and manufacture of APIs and advanced intermediates. Here, acetic anhydride serves as a key reagent in a synthesis step; ethyl acetate provides a dependable process and formulation solvent; and pyridine derivatives act as building blocks across multiple therapeutic classes, with CDMO programmes that carry molecules from route design through scale-up to GMP or non-GMP commercial production.

The company has a strong portfolio of bulk and fine ingredients used as intermediates in more than 280 APIs across various therapeutic segments. Being fully backwards integrated with most of these products, it provides cost-effective, reliable and long-term sustainable solutions to all its valued customers. For top pharmaceutical customers, it is their preferred partner.

Innovation is closely linked to customer programmes, especially in CDMOs. The firm has implemented AI-based retrosynthesis tools for faster route design and impurity prediction and has reported active progress across 40-45 pharmaceutical molecules.

With more than 30 Industry 4.0 use cases implemented across its operations, it has strengthened predictive maintenance, advanced process control, end-to-end digital integration and manufacturing traceability, thereby improving operational performance while meeting evolving global quality and compliance expectations.

As global innovators increasingly seek manufacturing partners that combine scientific expertise with digital maturity and sustainable operations, the company’s journey reflects the broader transformation underway across India’s CDMO ecosystem.

What CDMO 4.0 means for global innovators

For pharma and specialty chemical companies, the emergence of CDMO 4.0 represents significantly more than operational efficiency. It fundamentally changes how innovation is developed, transferred and commercialised. One of the most significant advantages lies in predictive process development. Through AI-powered analytics and digital twins, manufacturers can simulate process development and manufacturing scale-up long before physical batches are produced. Potential formulation challenges, equipment bottlenecks and process deviations can then be identified during virtual simulations, substantially reducing development risk while accelerating commercial readiness.

Likewise, technology transfer undergoes a dramatic transformation. Advanced digital integration between sponsor organisations and manufacturing partners enables process knowledge to move seamlessly across development sites, pilot facilities and commercial manufacturing locations. This shortens development timelines while reducing risks traditionally associated with process transfer between facilities.

Transparency is the other big differentiator. Instead of relying on periodic reports or post-production reviews, sponsors gain real-time visibility into manufacturing performance, batch progression, quality metrics and supply chain status through cloud-connected digital platforms. This ‘glass-box’ approach replaces traditional manufacturing opacity with continuous operational visibility, boosting confidence while simplifying regulatory oversight.

Predictive quality management further reduces operational risk. Continuous monitoring, AI-driven analytics and intelligent decision support systems identify process deviations before they become quality failures. Rather than investigating deviations after production, manufacturers prevent them altogether. The cumulative impact is substantial. Global innovators benefit from accelerated time-to-market, improved manufacturing reliability, lower operational risk, enhanced regulatory readiness and greater manufacturing flexibility across the product lifecycle.

More importantly, CDMO 4.0 enables the creation of long-term innovation ecosystems. Rather than engaging manufacturing partners on an individual project basis, pharma companies increasingly establish multi-year strategic collaborations spanning development, manufacturing, commercialisation and lifecycle management.

These collaborative ecosystems improve scalability, facilitate shared innovation and distribute development risk more effectively across both partner organisations. In the coming years, as product portfolios become more specialised and innovation cycles continue to shorten, such partnerships will become essential for sustaining long-term competitiveness across the globe.